蓝帆医疗
(002382)
| 流通市值：55.78亿 | | | 总市值：56.20亿 |
| 流通股本：10.00亿 | | | 总股本：10.07亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,477,911,477.13 | 6,253,168,236.58 | 4,654,357,096.34 | 3,005,595,271.23 |
| 营业收入 | 1,477,911,477.13 | 6,253,168,236.58 | 4,654,357,096.34 | 3,005,595,271.23 |
| 二、营业总成本 | 1,508,152,236.39 | 6,620,497,143.37 | 4,865,860,745.45 | 3,171,296,188.67 |
| 营业成本 | 1,224,199,609.93 | 5,222,701,975.08 | 3,855,177,720.39 | 2,518,802,038.74 |
| 税金及附加 | 12,143,832.56 | 42,138,967.02 | 32,131,109.21 | 22,102,491.17 |
| 销售费用 | 91,890,359.91 | 465,976,276.08 | 327,176,779.71 | 215,309,797.13 |
| 管理费用 | 69,509,328.6 | 348,509,007.38 | 240,582,619.09 | 155,269,672.88 |
| 研发费用 | 68,114,361 | 341,915,007.55 | 245,358,824.93 | 164,797,089.07 |
| 财务费用 | 42,294,744.39 | 199,255,910.26 | 165,433,692.12 | 95,015,099.68 |
| 其中:利息费用 | 70,545,959.16 | 278,979,702.23 | 206,191,854.31 | 131,491,787.83 |
| 其中:利息收入 | 6,962,972.45 | 30,384,815.97 | 20,810,832.04 | 13,881,122.23 |
| 加:公允价值变动收益 | 127,910,871.77 | 6,541,868.72 | -6,407.82 | 35,017.58 |
| 加:投资收益 | 1,798,623.76 | -7,474,359.78 | -7,721,768.26 | -7,232,200.88 |
| 资产处置收益 | 106,916.49 | -839,222.11 | -360,058.44 | 4,268.18 |
| 资产减值损失(新) | -45,865,732.57 | -53,735,642.88 | -15,345,677.01 | -12,508,886.92 |
| 信用减值损失(新) | 3,877,232.87 | -24,706,929.91 | -15,644,217.19 | -14,153,987.72 |
| 其他收益 | 13,905,108.26 | 30,979,097.13 | 22,020,165.74 | 18,277,090.11 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 71,492,261.32 | -416,564,095.62 | -228,561,612.09 | -181,279,617.09 |
| 加:营业外收入 | 394,778.73 | 21,298,978.61 | 18,764,827.6 | 18,253,090.46 |
| 减:营业外支出 | 883,092.6 | 6,338,794.4 | 4,525,038.97 | 3,354,531.53 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 71,003,947.45 | -401,603,911.41 | -214,321,823.46 | -166,381,058.16 |
| 减:所得税费用 | -11,529,996.09 | 63,317,316.2 | 12,601,948.52 | 2,076,580.86 |
| 六、净利润 | 82,533,943.54 | -464,921,227.61 | -226,923,771.98 | -168,457,639.02 |
| 持续经营净利润 | 82,533,943.54 | -464,921,227.61 | -226,923,771.98 | -168,457,639.02 |
| 归属于母公司股东的净利润 | 77,022,348.52 | -445,608,865.62 | -219,822,842.84 | -160,216,785.03 |
| 少数股东损益 | 5,511,595.02 | -19,312,361.99 | -7,100,929.14 | -8,240,853.99 |
| (一)基本每股收益 | 0.08 | -0.44 | -0.22 | -0.16 |
| (二)稀释每股收益 | 0.08 | -0.44 | -0.22 | -0.16 |
| 八、其他综合收益 | 2,412,969.11 | 27,426,379.65 | -32,979,291.84 | 9,581,758.86 |
| 归属于母公司股东的其他综合收益 | 2,556,983.3 | 22,518,852.99 | -25,647,369.57 | 8,697,743.72 |
| 九、综合收益总额 | 84,946,912.65 | -437,494,847.96 | -259,903,063.82 | -158,875,880.16 |
| 归属于母公司股东的综合收益总额 | 79,579,331.82 | -423,090,012.63 | -245,470,212.41 | -151,519,041.31 |
| 归属于少数股东的综合收益总额 | 5,367,580.83 | -14,404,835.33 | -14,432,851.41 | -7,356,838.85 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-30 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |